| Identification | Back Directory | [Name]
4-Piperidinemethanamine, N-[(1R,2S)-2-[2,3-dihydro-1-(phenylsulfonyl)-1H-indol-5-yl]cyclopropyl]-, rel- | [CAS]
2170212-33-4 | [Synonyms]
LSD1-IN-13
4-Piperidinemethanamine, N-[(1R,2S)-2-[2,3-dihydro-1-(phenylsulfonyl)-1H-indol-5-yl]cyclopropyl]-, rel- | [Molecular Formula]
C23H29N3O2S | [MOL File]
2170212-33-4.mol | [Molecular Weight]
411.56 |
| Hazard Information | Back Directory | [Uses]
LSD1-IN-13 (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC50 of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC50 of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines[1]. | [in vivo]
LSD1-IN-13 (compound 7e) (MV-4-11 xenograft mice, 0-20 mg/kg, Orally, daily for 15 days) suppresses tumor growth significantly in a dose-dependent manner[1]. | [References]
[1] Li C, et al. Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors. J Med Chem. 2022 Mar 10;65(5):4335-4349. DOI:10.1021/acs.jmedchem.1c02156 |
|
|